Study of oral rilzabrutinib for warm autoimmune hemolytic anemia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an oral medication (rilzabrutinib) against a placebo for people with warm autoimmune hemolytic anemia (wAIHA). It aims to see if the drug can help control the disease with fewer side effects than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with warm autoimmune hemolytic anemia (wAIHA) for at least 6 months.
- You must have not responded well to steroids, need high doses to stay stable, or cannot take steroids due to side effects or health reasons.
- You must be able to carry out daily activities (ECOG score 0 to 2).
- You cannot have certain cancers, infections (like hepatitis, HIV, TB), or other serious conditions that might interfere with the study.
- You cannot have had your spleen removed within the last 12 weeks or be planning surgery during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
This trial tests a targeted pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that has come back or not responded to standard treatments. It may help control your immune system's attack on your red blood cells.
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
This Phase 3 study tests a second-line treatment for adults with warm autoimmune hemolytic anemia whose disease is not controlled with steroids, who cannot tolerate steroids, or who decline standard treatment. It aims to improve anemia and reduce ongoing red blood cell destruction caused by the immune system.
Hear when a new Autoimmune Haemolytic Anaemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.